A Phase 3 interventional study of Matching Placebo to Ertugliflozin 5 mg and Matching Placebo to Ertugliflozin 10 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, and was the 14th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,233 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 9th largest by enrollment of the 170 interventional ones that give a count, is one of 6 that started in 2014, is one of 86 in phase 3, and was the 162nd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.
This study will include a 1-week screening period; an up to 12-week metformin titration/dose stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase A and 26-week Phase B) double-blind treatment period and a post-treatment telephone contact 14 days after the last dose of study medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
Drug: Matching Placebo to Ertugliflozin 10 mg · Drug: Ertugliflozin 5 mg · Drug: Sitagliptin 100 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication
Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Sitagliptin 100 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication
Ertugliflozin 5 mg, oral, once daily for 52 weeks
Drug: Matching Placebo to Ertugliflozin 10 mg · Drug: Matching Placebo to sitagliptin 100 mg · Drug: Ertugliflozin 5 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication
Ertugliflozin, oral, once daily for 52 weeks
Drug: Matching Placebo to sitagliptin 100 mg · Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication
Sitagliptin 100 mg, oral, once daily for 52 weeks
Drug: Matching Placebo to Ertugliflozin 5 mg · Drug: Matching Placebo to Ertugliflozin 10 mg · Drug: Sitagliptin 100 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication
Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Also known as: MK-8835, PF-04971729
Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Also known as: MK-8835, PF-04971729
Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Also known as: JANUVIA®
Drug page: Metformin
Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
Also known as: Glucophage, Glucophage XR
Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
Also known as: Lantus
Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
Also known as: AMARYL
Change From Baseline in A1C at Week 26: Excluding Rescue Approach
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
Time frame: Up to 54 weeks
Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
Time frame: Up to 52 weeks
Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach
This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach
Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach
A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time frame: Week 26
Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach
Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\] and model-based \[beta cell function and insulin secretion rate at 9 mM glucose\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\^-9 min\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time frame: 30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26
Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach
This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 26
The trial was conducted in 21 countries and included 242 trial centers.
| Milestone | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Started | 250 | 248 | 247 | 243 | 245 |
| Treated | 250 | 248 | 247 | 243 | 244 |
| Completed | 226 | 217 | 219 | 221 | 218 |
| Not completed | 24 | 31 | 28 | 22 | 27 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 3 | 1 |
| Withdrew: Participant moved | 1 | 1 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 7 | 11 | 13 | 9 | 13 |
| Withdrew: Adverse event | 3 | 5 | 2 | 3 | 2 |
| Withdrew: Lost to follow-up | 6 | 12 | 11 | 5 | 6 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 3 | 0 | 1 | 2 | 1 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
| Percentage | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Change From Baseline in A1C at Week 26: Excluding Rescue Approach | -1.02 (-1.14 to -0.90) | -1.08 (-1.20 to -0.96) | -1.05 (-1.17 to -0.93) | -1.49 (-1.61 to -1.36) | -1.52 (-1.64 to -1.40) |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach | 62.0 | 57.7 | 57.5 | 58.8 | 55.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach | 3.2 | 3.2 | 2.8 | 3.3 | 3.7 |
This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
| Kilograms | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach | -2.69 (-3.13 to -2.25) | -3.74 (-4.18 to -3.29) | -0.67 (-1.12 to -0.22) | -2.52 (-2.97 to -2.07) | -2.94 (-3.39 to -2.49) |
Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach | -35.73 (-40.04 to -31.42) | -36.91 (-41.21 to -32.62) | -25.56 (-29.93 to -21.19) | -43.96 (-48.29 to -39.63) | -48.70 (-53.01 to -44.39) |
A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach | 26.4 | 31.9 | 32.8 | 52.3 | 49.2 |
Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\] and model-based \[beta cell function and insulin secretion rate at 9 mM glucose\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\^-9 min\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
| SBCSGI (10^-9min^-1) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach | 8.62 (1.28 to 15.96) | 9.71 (2.29 to 17.13) | 21.11 (13.55 to 28.67) | 16.24 (8.36 to 24.11) | 11.51 (3.76 to 19.26) |
This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
| mm Hg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach | -3.89 (-5.28 to -2.50) | -3.69 (-5.08 to -2.30) | -0.66 (-2.07 to 0.76) | -3.42 (-4.82 to -2.03) | -3.67 (-5.06 to -2.29) |
Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 5 mg | — | 12/250 (4.8%) | 36/250 (14.4%) |
| Ertugliflozin 15 mg | — | 5/248 (2%) | 43/248 (17.3%) |
| Sitagliptin 100 mg | — | 8/247 (3.2%) | 28/247 (11.3%) |
| Ertugliflozin 5 mg + Sitagliptin 100 mg | — | 9/243 (3.7%) | 31/243 (12.8%) |
| Ertugliflozin 15 mg + Sitagliptin 100 mg | — | 12/244 (4.9%) | 38/244 (15.6%) |
| Event | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/250 | 0/248 | 1/247 | 0/243 | 2/244 |
| VomitingGastrointestinal disorders | 2/250 | 0/248 | 0/247 | 0/243 | 0/244 |
| Blood potassium decreasedInvestigations | 0/250 | 0/248 | 0/247 | 1/243 | 0/244 |
| Blood sodium decreasedInvestigations | 0/250 | 0/248 | 0/247 | 1/243 | 0/244 |
| Acute coronary syndromeCardiac disorders | 1/250 | 0/248 | 0/247 | 1/243 | 0/244 |
| Myocardial infarctionCardiac disorders | 0/250 | 0/248 | 1/247 | 1/243 | 1/244 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/250 | 0/248 | 0/247 | 1/243 | 0/244 |
| Ischaemic strokeNervous system disorders | 0/250 | 1/248 | 1/247 | 1/243 | 0/244 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/250 | 0/248 | 0/247 | 1/243 | 0/244 |
| NephrolithiasisRenal and urinary disorders | 0/250 | 0/248 | 0/247 | 1/243 | 0/244 |
| Event | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg |
|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 12/250 | 13/248 | 11/247 | 9/243 | 20/244 |
| Urinary tract infectionInfections and infestations | 20/250 | 19/248 | 13/247 | 14/243 | 8/244 |
| NasopharyngitisInfections and infestations | 6/250 | 13/248 | 6/247 | 12/243 | 12/244 |
The Baseline Analysis Population was the All-Participants-As-Treated population. One participant randomized to the Ertugliflozin 15 mg + Sitagliptin 100 mg arm did not receive study medication.
| Age, Continuous(Years) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 55.1 ± 10.1 | 55.3 ± 9.5 | 54.8 ± 10.7 | 55.2 ± 10.4 | 55.1 ± 9.8 | 55.1 ± 10.1 |
| Sex: Female, Male(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Female | 123 | 114 | 93 | 120 | 118 | 568 |
| Male | 127 | 134 | 154 | 123 | 126 | 664 |
| Baseline Hemoglobin A1C (A1C)(Percent) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 8.6 ± 1.0 | 8.6 ± 1.0 | 8.5 ± 1.0 | 8.6 ± 1.0 | 8.6 ± 1.0 | 8.6 ± 1.0 |
| Baseline Body Weight(Kilograms) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 88.6 ± 22.2 | 88.0 ± 20.3 | 89.8 ± 23.4 | 89.5 ± 20.8 | 87.5 ± 20.5 | 88.7 ± 21.5 |
| Baseline Fasting Plasma Glucose(mg/dL) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 184.1 ± 52.2 | 179.5 ± 45.7 | 177.4 ± 46.6 | 183.8 ± 44.3 | 177.2 ± 49.4 | 180.4 ± 47.8 |
| Static Beta-Cell Sensitivity to Glucose Index(SBCSGI (10^-9min^-1)) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 20.9 ± 26.1 | 18.0 ± 16.3 | 20.2 ± 21.2 | 20.0 ± 16.6 | 19.3 ± 21.0 | 19.7 ± 20.5 |
| Sitting Systolic Blood Pressure(mm Hg) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 129.7 ± 12.5 | 128.9 ± 12.5 | 128.3 ± 12.2 | 130.2 ± 12.6 | 129.1 ± 13.3 | 129.3 ± 12.6 |
| Baseline estimated glomerular filtration rate, eGFR(mL/min/1.73m^2) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Sitagliptin 100 mg | Ertugliflozin 5 mg + Sitagliptin 100 mg | Ertugliflozin 15 mg + Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 91.9 ± 20.6 | 92.8 ± 21.4 | 92.6 ± 18.2 | 91.9 ± 20.4 | 92.6 ± 19.2 | 92.4 ± 20.0 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Apr 2014 to primary completion in May 2016, 25 months.
Results were first posted in Nov 2017, 1 year 5 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ertugliflozin · Sitagliptin